Summit Therapeutics (SMMT) is trading higher as investors react to fresh attention on ivonescimab’s Phase III profile in advanced non-small cell lung cancer (NSCLC), including outcomes in patients with baseline brain metastases, and a clearer U.S. regulatory timeline. The latest catalyst is a renewed data-and-regulatory setup into the 2026 European Lung Cancer Congress (ELCC 2026) and the company’s pending FDA decision window.

Ahead of ELCC 2026, Summit said Phase III HARMONi trial analyses will be presented, including intracranial efficacy results in EGFR TKI–resistant, EGFR-mutated NSCLC patients with and without asymptomatic brain metastases at baseline. A widely circulated summary of the announcement highlighted intracranial progression-free survival of 10.1 months for ivonescimab plus chemotherapy versus 6.5 months for chemotherapy in patients with baseline brain metastases (hazard ratio 0.53; nominal p=0.0068), putting brain-metastases control back at the center of the ivonescimab narrative.

Summit has said the FDA accepted its Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated, locally advanced or metastatic non-squamous NSCLC after prior EGFR TKI therapy, setting a PDUFA goal action date of November 14, 2026. With a hard regulatory date in place, the stock can trade as an “event-driven” name, with incremental clinical readouts and conference visibility potentially amplifying positioning into the decision.

Near-term, investors are monitoring the visibility and tone of ELCC 2026 posters, especially any details on intracranial activity, durability, and safety that could influence how the market sizes ivonescimab’s differentiation. Beyond ELCC, the next major rerating catalysts are additional Phase III timeline updates (including HARMONi-3 planning milestones) and any FDA communication that changes the risk profile into the November 14, 2026 PDUFA goal date.